Key patents on Glutaminyl Cyclase (QC) inhibition for the treatment of Alzheimer’s disease granted in Japan
Probiodrug AG to publish its First Quarter 2015 Business Update on May 13, 2015
GTC 9th Drug Design & Medicinal Chemistry Conference, 5-6 May 2015, Berlin, Germany
HALLE/SAALE, Germany, 05 May 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, today announced that Ulrich Heiser, PhD, Director Medicinal Chemistry/CMC at Probiodrug AG has been invited to present at the GTC 9th Drug Design & Medicinal Chemistry Conference, taking place from May 5-6, 2015 in Berlin, Germany.
The presentation entitled, “Glutaminyl Cyclase Inhibition: A New Approach for the Treatment of AD” is scheduled within Session 2 “Emerging Targets for Therapeutic Intervention” on Tuesday, May 5th 2015 from 11.50 am to 12.40 pm.
The presentation will introduce the key concept of Probiodrug’s new approach for AD treatment, as well as information on the identification of the lead compound PQ912. The presentation addresses the medicinal chemistry strategy as well as pre-clinical in vitro and in vivo efficacy data. Furthermore, results from the successfully completed Phase I clinical trial for PQ912 will be presented.
For more information please visit https://www.gtcbio.com/conferences/drug-design-medicinal-chemistry-agenda.
###
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume Brophy
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 (0) 203 440 5653
Email: probiodrug@humebrophy.com
Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research. www.probiodrug.de
About Alzheimer’s disease
Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 44 million people worldwide currently live with the condition and this number is expected to almost double by 2030 and to more than triple by 2050 to over 132 million. Alzheimer’s also has an estimated, global societal cost of over $600 billion (World Alzheimer Report 2014).
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.